Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 2Suspended 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Basal Cell Nevus Syndrome 3Carcinoma, Basal Cell 2Skin Neoplasms 1Lymphoma, Follicular 1Lupus Erythematosus, Systemic 1

Interventions

sonidegib 3gusacitinib 3IPI-926 3HhAntag691 3tazarotene 2Photochemotherapy 2Drug Evaluation 2Aminolevulinic Acid 21-phenyl-3,3-dimethyltriazene 2merphos 1Vincristine 1Solutions 1Sirolimus 1Red Light 1Nivolumab 1NVP-BKM120 1Microarray Analysis 1Methotrexate 1Mental Status and Dementia Tests 1Mass Spectrometry 1Ipilimumab 1Gene Expression Profiling 1Fluorouracil 1Etoposide 1Cyclophosphamide 1Comparative Genomic Hybridization 1Carnitine 1Carboplatin 1Blue Light 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Basal Cell Nevus Syndrome × gusacitinib × Clear all
NCT04416516 2024-04-10

Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor

Ascend Biopharmaceuticals Ltd

Phase 2 Completed
21 enrolled
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT03208296 2023-02-06

Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)

Ascend Biopharmaceuticals Ltd

Phase 1/2 Suspended
24 enrolled
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT02550678 2018-06-06

ASN-002-001

Ascend Biopharmaceuticals Ltd

Phase 1/2 Completed
16 enrolled
Dermatologic

Basal Cell Nevus Syndrome, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡